Equities analysts predict that ArQule, Inc. (NASDAQ:ARQL) will announce earnings of ($0.09) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ArQule’s earnings. ArQule reported earnings of ($0.10) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 10%. The business is scheduled to issue its next quarterly earnings results on Tuesday, March 6th.
According to Zacks, analysts expect that ArQule will report full year earnings of ($0.39) per share for the current year. For the next year, analysts expect that the firm will report earnings of ($0.35) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover ArQule.
ArQule (NASDAQ:ARQL) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. During the same period in the previous year, the firm earned ($0.08) earnings per share.
Several equities analysts have recently commented on ARQL shares. Zacks Investment Research lowered ArQule from a “buy” rating to a “hold” rating in a research note on Wednesday, September 27th. ValuEngine lowered ArQule from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
Shares of ArQule (NASDAQ ARQL) traded down $0.01 during trading hours on Wednesday, reaching $1.29. The company’s stock had a trading volume of 699,400 shares, compared to its average volume of 192,458. The company has a debt-to-equity ratio of 2.33, a current ratio of 3.45 and a quick ratio of 3.45. ArQule has a 12 month low of $0.92 and a 12 month high of $1.68.
Institutional investors have recently made changes to their positions in the company. Curbstone Financial Management Corp lifted its stake in shares of ArQule by 100.0% in the 3rd quarter. Curbstone Financial Management Corp now owns 104,572 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 52,286 shares during the last quarter. Northern Trust Corp lifted its stake in ArQule by 0.9% during the 2nd quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 1,385 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in ArQule during the 3rd quarter worth about $2,220,000. Finally, First Eagle Investment Management LLC lifted its stake in ArQule by 5.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 12,438,996 shares of the biotechnology company’s stock worth $13,807,000 after acquiring an additional 591,421 shares in the last quarter. 61.83% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://sportsperspectives.com/2017/11/15/analysts-expect-arqule-inc-arql-to-announce-0-09-earnings-per-share.html.
ArQule Company Profile
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.